(Q36223650)

English

Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

4 references

25 April 2019

30 June 2019

7 November 2019

26 October 2020

Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

relapsing-remitting multiple sclerosis

4 references

25 April 2019

30 June 2019

7 November 2019

26 October 2020

1 reference

7 November 2019

1 reference

7 November 2019

immunosuppressive drug

1 reference

26 October 2020

corrigendum / erratum

Erratum to: Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group

0 references

1

object named as

Franz Fazekas

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

author name string

Thomas Berger

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Tanja Hojs Fabjan

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Alenka Horvat Ledinek

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Gábor Jakab

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Samuel Komoly

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Jörg Kraus

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Egon Kurča

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Theodoros Kyriakides

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

L'ubomír Lisý

10

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Ivan Milanov

11

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Panayiotis Panayiotou

12

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sasa Sega Jazbec

13

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Radomír Taláb

14

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Latchezar Traykov

15

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Peter Turčáni

16

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Karl Vass

17

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Norbert Vella

18

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Eva Havrdová

19

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

16 August 2012

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1 August 2012

4 references

25 April 2019

30 June 2019

7 November 2019

26 October 2020

Wiener Medizinische Wochenschrift

5 references

Europe PubMed Central

PMC publication ID

12 August 2017

25 April 2019

30 June 2019

7 November 2019

26 October 2020

162

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

15-16

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

354-366

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Development of oral immunomodulatory agents in the management of multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Fingolimod is a potential novel therapy for multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Multiple sclerosis - established and novel therapeutic approaches

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

National MS registries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Disease-modifying agents for multiple sclerosis: recent advances and future prospects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Identification and development of new therapeutics for multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Central nervous system-directed effects of FTY720 (fingolimod).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Effect of relapses on development of residual deficit in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

1 October 2017

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438392

29 June 2018

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0123-Y

21 January 2018

Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report

1 reference

https://pubmed.ncbi.nlm.nih.gov/22895849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22895849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22895849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22895849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

https://pubmed.ncbi.nlm.nih.gov/22895849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/22895849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Emerging oral drugs for multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22895849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10354-012-0123-Y

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36223650&oldid=2198406188"